Wells Fargo Adds Merck (MRK) to Q1 2026 Tactical List Ahead of Key Catalysts [Yahoo! Finance]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Yahoo! Finance
On January 5, Wells Fargo added Merck & Co., Inc. (NYSE:MRK) to its Q1 2026 Tactical Ideas List. Wells said Merck is moving into what it calls a catalyst-rich stretch across FY26 and 2027. The firm expects the stock to find a footing once 2026 guidance clears a near-term overhang. That could open the door for investors ahead of key events in the first half of 2026, including detailed CADENCE results and Phase 3 CD388 data. Wells has an Overweight rating on the shares and a $125 price target. Merck & Co., Inc. (NYSE:MRK) rose nearly 8% in 2025, though the story is not without risk. The company's flagship cancer drug, Keytruda, is set to lose US patent protection in 2028. International patents extend into the early 2030s, and a newer version of the drug carries protections into the late 2030s. Those layers help soften the longer-term impact of the patent cliff. The company has also stayed active on the deal front. Merck recently agreed to acquire Cidara Therapeutics for about $9 bi
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- JPM26: US biotech's ‘Sputnik moment,' Pfizer's obesity ambitions and Bristol Myers' big year [Yahoo! Finance]Yahoo! Finance
- Healthcare Leader Fred Hassan Appointed Executive Chair of NorstellaPR Web
- 1 Momentum Stock Worth Your Attention and 2 Facing Headwinds [Yahoo! Finance]Yahoo! Finance
- Cancer Drugs Drive Nearly One-Fifth Of Pharma Sales [zero hedge]zero hedge
- 3 Dividend Stocks to Hold for the Next 10 Years [Yahoo! Finance]Yahoo! Finance
MRK
Earnings
- 10/30/25 - Beat
MRK
Sec Filings
- 1/5/26 - Form 4
- 1/5/26 - Form 4
- 1/5/26 - Form 4
- MRK's page on the SEC website